MX371417B - Composiciones de profarmacos de aripiprazol. - Google Patents
Composiciones de profarmacos de aripiprazol.Info
- Publication number
- MX371417B MX371417B MX2017002029A MX2017002029A MX371417B MX 371417 B MX371417 B MX 371417B MX 2017002029 A MX2017002029 A MX 2017002029A MX 2017002029 A MX2017002029 A MX 2017002029A MX 371417 B MX371417 B MX 371417B
- Authority
- MX
- Mexico
- Prior art keywords
- aripiprazole prodrug
- prodrug
- surface stabilizer
- aripiprazole
- particles
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Abstract
Se describe una composición que comprende (a) una población de partículas de un profármaco de aripiprazol que tiene un tamaño de partícula basado en el volumen (Dv50) de menos de 1000 nm y (b) por lo menos un estabilizador de superficie que comprende un componente adsorbido que se adsorbe en la superficie de las partículas del profármaco de aripiprazol y un componente libre disponible para la solubilización del profármaco de aripiprazol; la proporción del estabilizador de superficie con el profármaco proporciona la cantidad óptima de estabilizador de superficie libre con la finalidad de producir una formulación inicial de estudio; también se describen los métodos de tratamiento que utilizan la composición antes mencionada.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462038665P | 2014-08-18 | 2014-08-18 | |
EP14181328 | 2014-08-18 | ||
PCT/EP2015/068872 WO2016026822A1 (en) | 2014-08-18 | 2015-08-17 | Aripiprazole prodrug compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2017002029A MX2017002029A (es) | 2017-08-14 |
MX371417B true MX371417B (es) | 2020-01-29 |
Family
ID=51352472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017002029A MX371417B (es) | 2014-08-18 | 2015-08-17 | Composiciones de profarmacos de aripiprazol. |
Country Status (21)
Country | Link |
---|---|
US (1) | US20220079939A1 (es) |
EP (2) | EP3182958B2 (es) |
JP (1) | JP6571166B2 (es) |
CN (3) | CN112494492B (es) |
AU (1) | AU2015306198B2 (es) |
BR (1) | BR112017002926A2 (es) |
CA (1) | CA2957762A1 (es) |
CY (1) | CY1124625T1 (es) |
DK (1) | DK3508196T3 (es) |
ES (1) | ES2884849T3 (es) |
HR (1) | HRP20211271T1 (es) |
HU (1) | HUE055711T2 (es) |
IL (2) | IL292079B1 (es) |
MX (1) | MX371417B (es) |
NZ (2) | NZ767204A (es) |
PL (2) | PL3182958T5 (es) |
PT (1) | PT3508196T (es) |
RS (2) | RS62232B1 (es) |
RU (1) | RU2705376C2 (es) |
SI (2) | SI3508196T1 (es) |
WO (1) | WO2016026822A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3182958T4 (da) * | 2014-08-18 | 2022-07-04 | Alkermes Pharma Ireland Ltd | Aripiprazol-prodrugsammensætninger |
US10016415B2 (en) | 2014-08-18 | 2018-07-10 | Alkermes Pharma Ireland Limited | Aripiprazole prodrug compositions |
CA3014788A1 (en) * | 2016-02-17 | 2017-08-24 | Alkermes Pharma Ireland Limited | Compositions of multiple aripiprazole prodrugs |
CN110025572A (zh) * | 2018-01-11 | 2019-07-19 | 四川科伦药物研究院有限公司 | 月桂酰阿立哌唑混悬剂及其制备方法 |
EP3761983A1 (en) * | 2018-03-05 | 2021-01-13 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
CN110327296B (zh) * | 2019-08-06 | 2021-10-22 | 深圳市泛谷药业股份有限公司 | 一种阿立哌唑长效注射制剂及其制备方法 |
AU2022288895A1 (en) | 2021-06-08 | 2024-01-18 | Chugai Seiyaku Kabushiki Kaisha | Formulation containing dihydropyridazine-3,5-dione derivative |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
AU660852B2 (en) | 1992-11-25 | 1995-07-06 | Elan Pharma International Limited | Method of grinding pharmaceutical substances |
US5336507A (en) | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
TW384224B (en) | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
US5718388A (en) | 1994-05-25 | 1998-02-17 | Eastman Kodak | Continuous method of grinding pharmaceutical substances |
US5560932A (en) | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
US5665331A (en) | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
US5662883A (en) | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
US5534270A (en) | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
US5543133A (en) | 1995-02-14 | 1996-08-06 | Nanosystems L.L.C. | Process of preparing x-ray contrast compositions containing nanoparticles |
DE69637441T2 (de) | 1995-10-17 | 2009-03-05 | Jagotec Ag | Verabreichung unlöslicher arzneistoffe |
GB9622173D0 (en) | 1996-10-24 | 1996-12-18 | Glaxo Group Ltd | Particulate Products |
DE60222160T2 (de) * | 2001-10-12 | 2008-06-12 | Elan Pharma International Ltd., Athlone | Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung |
US20050032811A1 (en) * | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
PT1675573E (pt) * | 2003-10-23 | 2008-12-30 | Otsuka Pharma Co Ltd | Formulação de iripiprazole injectável estéril de libertação controlada e um processo para a sua preparação |
EP2279727A3 (en) * | 2005-09-15 | 2011-10-05 | Elan Pharma International Limited | Nanoparticulate aripiprazole formulations |
LT2445502T (lt) | 2009-06-25 | 2017-09-25 | Alkermes Pharma Ireland Limited | Heterocikliniai junginiai, skirti neurologinių ir fiziologinių susirgimų gydymui |
CA2830511C (en) * | 2011-03-18 | 2021-09-14 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising aripiprazole lauroxil and sorbitan laurate |
CA2867121C (en) * | 2012-03-19 | 2021-05-25 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
US9999670B2 (en) * | 2012-03-19 | 2018-06-19 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising benzyl alcohol |
EP3718536A1 (en) * | 2012-09-19 | 2020-10-07 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
-
2015
- 2015-08-17 NZ NZ767204A patent/NZ767204A/en unknown
- 2015-08-17 HU HUE19154013A patent/HUE055711T2/hu unknown
- 2015-08-17 RS RS20210956A patent/RS62232B1/sr unknown
- 2015-08-17 JP JP2017509024A patent/JP6571166B2/ja active Active
- 2015-08-17 RU RU2017108204A patent/RU2705376C2/ru active
- 2015-08-17 DK DK19154013.7T patent/DK3508196T3/da active
- 2015-08-17 CN CN202011416673.7A patent/CN112494492B/zh active Active
- 2015-08-17 RS RS20190505A patent/RS58746B2/sr unknown
- 2015-08-17 IL IL292079A patent/IL292079B1/en unknown
- 2015-08-17 WO PCT/EP2015/068872 patent/WO2016026822A1/en active Application Filing
- 2015-08-17 CA CA2957762A patent/CA2957762A1/en active Pending
- 2015-08-17 AU AU2015306198A patent/AU2015306198B2/en active Active
- 2015-08-17 NZ NZ728914A patent/NZ728914A/en unknown
- 2015-08-17 EP EP15750750.0A patent/EP3182958B2/en active Active
- 2015-08-17 SI SI201531670T patent/SI3508196T1/sl unknown
- 2015-08-17 CN CN202011448652.3A patent/CN112641785A/zh active Pending
- 2015-08-17 PL PL15750750.0T patent/PL3182958T5/pl unknown
- 2015-08-17 PT PT191540137T patent/PT3508196T/pt unknown
- 2015-08-17 SI SI201530711T patent/SI3182958T2/sl unknown
- 2015-08-17 MX MX2017002029A patent/MX371417B/es active IP Right Grant
- 2015-08-17 HR HRP20211271TT patent/HRP20211271T1/hr unknown
- 2015-08-17 EP EP19154013.7A patent/EP3508196B1/en active Active
- 2015-08-17 PL PL19154013T patent/PL3508196T3/pl unknown
- 2015-08-17 BR BR112017002926A patent/BR112017002926A2/pt not_active Application Discontinuation
- 2015-08-17 ES ES19154013T patent/ES2884849T3/es active Active
- 2015-08-17 CN CN201580055491.2A patent/CN106794251B/zh active Active
-
2017
- 2017-02-14 IL IL250607A patent/IL250607B/en unknown
-
2021
- 2021-08-23 CY CY20211100753T patent/CY1124625T1/el unknown
- 2021-10-12 US US17/450,683 patent/US20220079939A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX371417B (es) | Composiciones de profarmacos de aripiprazol. | |
IL281424A (en) | Microbiota restoration treatment preparations and production methods | |
EP3277769A4 (en) | Compositions and methods for the stabilization of clay-containing soils | |
EP3362467A4 (en) | IMMUNOGENIC COMPOSITIONS AGAINST PORCINIC CIRCOVIRUS TYPE 3 AND METHODS OF MAKING AND USING SAME | |
EP3374494A4 (en) | CRISPR COMPOSITIONS AND METHODS OF USE FOR GENE THERAPY | |
MX2017016322A (es) | Metodos para tratar tumores de celulas epitelioides. | |
MX2015011783A (es) | Metodos para tratar tumores solidos pediatricos. | |
IL248363B (en) | Preparations containing a high dose of a tetracyclic compound, methods for their preparation and their uses | |
EP3458074A4 (en) | COMPOSITIONS FOR DISPENSING TRNA NANOPARTICLES AND METHOD FOR USE THEREOF | |
NZ712350A (en) | Abiraterone acetate formulation | |
PH12017500555A1 (en) | Modified phosphpors and compositions thereof | |
EP3556858A3 (en) | Crispr/cas-related methods and compositions for treating cystic fibrosis | |
MX2015012882A (es) | Compuestos y composiciones terapeuticos. | |
EP3155080A4 (en) | Nano-tribology compositions and related methods including hard particles | |
EP3136875A4 (en) | Small particle sized protein compositions and methods of making | |
MX2017015127A (es) | Particulas modificadas por carbohidratos y formulaciones en particulas para modular una respuesta inmunitaria. | |
EP2964032A4 (en) | COMPOSITIONS AND METHOD FOR THE PRODUCTION OF VIRUSELIC PARTICLES | |
EP3277269A4 (en) | Methods for prevention and treatment of cardiometabolic syndrome and compositions used therein | |
EP3600277A4 (en) | COMPOSITIONS FOR TREATMENT OF DRUG-RESISTANT TUMORS AND METHOD OF USING THEREOF | |
MX2019004059A (es) | Preparacion de absorbedores de uv de tamaño nanometrico. | |
MX2020002793A (es) | Composiciones de microesferas de gas encapsulado en lipidos y metodos relacionados. | |
MX2015017539A (es) | Composiciones nanoparticuladas y formulaciones de compuestos de piperazina. | |
MX2018011016A (es) | Formulaciones estables para liofilizar particulas terapeuticas. | |
CY1121594T1 (el) | Συνθεσεις προφαρμακου αριπιπραζολης | |
EP3468755A4 (en) | SUB-MICRONIC PARTICLE COMPOSITIONS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |